News
| 6 November 2018 |
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018Initiated a Phase 2 trial of RPL554 as add-on to dual bronchodilator therapy for COPD maintenance treatment; enrolled last patient and dosing underway |
| 31 October 2018 |
Verona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance TreatmentEnrollment complete ahead of schedule |
| 30 October 2018 |
Verona Pharma to Announce Interim Results for Nine Months Ended September 30, 2018 and Provide Clinical Development UpdateLONDON, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will report… |
| 26 October 2018 |
Data from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis Presented at North American Cystic Fibrosis ConferencePre-clinical findings show RPL554 stimulates rare class III and IV CFTR mutants |
| 27 September 2018 |
Verona Pharma to Host Investor & Analyst R&D Forum on October 12, 2018LONDON, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announc… |
| 20 September 2018 |
Issue of Shares & PDMR AnnouncementLONDON, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it today issued… |
| 13 September 2018 |
Verona Pharma to Host Conference Call to Review Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD Presented at European Respiratory Society International CongressLONDON, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Jan-A… |
| 12 September 2018 |
Verona Pharma to Present Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD at European Respiratory Society International CongressLONDON, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces it will present… |
| 6 September 2018 |
Verona Pharma Announces Publication of Key Paper on RPL554 in COPD in the European Respiratory JournalLONDON, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today… |
| 10 August 2018 |
PDMR Dealing & Issue of SharesLONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on November 29,… |
Targeting unmet needs
384m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients
Read more about COPD and CF in the unmet needs section of this website
The Lancet Respiratory Medicine
Peer-reviewed paper in the Lancet's highly-respected medication journal
Basic & Clinical Pharmacology & Toxicology
Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD
Verona Pharma plc
3 More London Riverside,
London SE1 2RE
T: +44 (0)203 283 4200
E: info@veronapharma.com
© Verona Pharma plc 2018
